Novartis Q1 profit down on US generic erosion

Swiss drugmaker Novartis ​reported first-quarter ‌core operating profit below market ​expectations ​on Tuesday, as generic ⁠competition ​for its ​top-selling heart drug Entresto weighed ​on sales.